Liens rapides
Catégories
Fiches d'information
Les fiches d'information fournissent des informations supplémentaires sur l'industrie mondiale des protéines plasmatiques thérapeutiques.
Publications et présentations
Discover the main highlights of our industry in our latest publications.
Ressources pour les patients
Explorez les ressources de PPTA pour les patients intéressés par les thérapies aux protéines plasmatiques.
Rapports des parties prenantes
Apprenez-en plus en accédant à la collection de rapports de l'industrie.
Actualités et communiqués de presse
Restez au courant de l'actualité et des événements de l'Association.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mar 10, 2021
New position statement by CHMP regarding donor deferral criteria for sexual behaviour helps assessment of PMFs
The International Plasma and Fractionation Association and the Plasma Protein Therapeutics Association are pleased with the recent publication by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) "CHMP Position statement on quality and safety assessment for the Plasma Master File (PMF) certification with regard to donor deferral criteria for sexual risk behaviour," as such a position was highly needed, especially regarding men-having-sex-with-men (MSM).
All
PPTA statements
Mar 10, 2021
New position statement by CHMP regarding donor deferral criteria for sexual behaviour helps assessment of PMFs
The International Plasma and Fractionation Association and the Plasma Protein Therapeutics Association are pleased with the recent publication by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) "CHMP Position statement on quality and safety assessment for the Plasma Master File (PMF) certification with regard to donor deferral criteria for sexual risk behaviour," as such a position was highly needed, especially regarding men-having-sex-with-men (MSM).
All
PPTA statements
Mar 4, 2021
Immunoglobulin Replacement Therapy Cost-Effectiveness Study
Common variable immunodeficiency disorders (CVID), the most common form of primary antibody deficiency, are rare conditions associated with considerable morbidity and mortality.
All
Publication
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247941
Mar 4, 2021
Immunoglobulin Replacement Therapy Cost-Effectiveness Study
Common variable immunodeficiency disorders (CVID), the most common form of primary antibody deficiency, are rare conditions associated with considerable morbidity and mortality.
All
Publication
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247941
Mar 1, 2021
The Source Spring 2021
Magazine of the plasma protein therapeutics industry - Spring 2021
All
The Source Magazine
https://drive.google.com/file/d/1yqFqdfQu0EonQT7d-uQqXcVJfZ9ykOk9/view?usp=sharing
Mar 1, 2021
The Source Spring 2021
Magazine of the plasma protein therapeutics industry - Spring 2021
All
The Source Magazine
https://drive.google.com/file/d/1yqFqdfQu0EonQT7d-uQqXcVJfZ9ykOk9/view?usp=sharing
Feb 25, 2021
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients
February 25, 2021 (Annapolis, MD) — The Plasma Protein Therapeutics Association (PPTA) welcomes the decision of the UK government to lift a two decades old ban on the use of UK-donated plasma for the manufacture of immunoglobulins, following a scientific review conducted by the Medicines and Healthcare Products Regulatory Agency.
All
Press releases
Feb 25, 2021
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients
February 25, 2021 (Annapolis, MD) — The Plasma Protein Therapeutics Association (PPTA) welcomes the decision of the UK government to lift a two decades old ban on the use of UK-donated plasma for the manufacture of immunoglobulins, following a scientific review conducted by the Medicines and Healthcare Products Regulatory Agency.
All
Press releases
Aucun résultat n'a été trouvé